BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15701341)

  • 1. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy.
    Moreira AP; Duarte LH; Vieira F; João F; Lima JP
    Rev Esp Med Nucl; 2005; 24(1):14-8. PubMed ID: 15701341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms.
    Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
    Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
    Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
    Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
    Shaverdian N; Pinchot SN; Zarebczan B; Gillis HC; Schiro A; Chen H
    Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
    Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
    Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
    Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
    Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (111)In-pentetreotide SPET/CT in carcinoid tumours: is the role of hybrid systems advantageous in abdominal or thoracic lesions?
    Tranfaglia C; Cardinali L; Gattucci M; Scialpi M; Ferolla P; Sinzinger H; Palumbo B
    Hell J Nucl Med; 2011; 14(3):274-7. PubMed ID: 22087449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
    Chajari M; Lacroix J; Peny AM; Chesnay E; Batalla A; Henry-Amar M; Delcambre C; Génot JY; Fruchard C; Bardet S
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):380-7. PubMed ID: 12002715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
    Lebtahi R; Le Cloirec J; Houzard C; Daou D; Sobhani I; Sassolas G; Mignon M; Bourguet P; Le Guludec D
    J Nucl Med; 2002 Jul; 43(7):889-95. PubMed ID: 12097458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
    Wong KK; Cahill JM; Frey KA; Avram AM
    Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.
    Castaldi P; Rufini V; Treglia G; Bruno I; Perotti G; Stifano G; Barbaro B; Giordano A
    Radiol Med; 2008 Oct; 113(7):1056-67. PubMed ID: 18797822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
    Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
    Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPET/CT image co-registration in the abdomen with a simple and cost-effective tool.
    Förster GJ; Laumann C; Nickel O; Kann P; Rieker O; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):32-9. PubMed ID: 12483407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
    Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
    Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.